Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Marvel Biosciences Corp (MRVL.VN)

Marvel Biosciences Corp (MRVL.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 5,598
  • Shares Outstanding, K 44,786
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,291 K
  • 60-Month Beta 0.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade MRVL.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.06
  • Most Recent Earnings $-0.01 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.100 +25.00%
on 07/12/24
0.130 -3.85%
on 07/23/24
+0.010 (+8.70%)
since 06/26/24
3-Month
0.060 +108.33%
on 05/17/24
0.155 -19.35%
on 05/03/24
-0.020 (-13.79%)
since 04/26/24
52-Week
0.010 +1,150.00%
on 10/02/23
0.190 -34.21%
on 02/07/24
+0.045 (+56.25%)
since 07/26/23

Most Recent Stories

More News
Marvel Biosciences Announces Stock Option Grants

Calgary, Alberta--(Newsfile Corp. - July 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), announce...

MBCOF : 0.0809 (-29.22%)
MRVL.VN : 0.125 (unch)
Marvel Announces an Extension to Its Collaboration with The iBraiN Institute to Test MB204 In a Pre-Clinical Model of Rett Syndrome

Calgary, Alberta--(Newsfile Corp. - July 24, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.0809 (-29.22%)
MRVL.VN : 0.125 (unch)
Marvel Biosciences Closes Private Placement

Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased...

MBCOF : 0.0809 (-29.22%)
MRVL.VN : 0.125 (unch)
Marvel Highlights New Published Research of Its SAB Member Professor David Blum

Calgary, Alberta--(Newsfile Corp. - July 9, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.0809 (-29.22%)
MRVL.VN : 0.125 (unch)
Marvel Biosciences Announces Private Placement Update

Calgary, Alberta--(Newsfile Corp. - June 21, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), wishes to...

MBCOF : 0.0809 (-29.22%)
MRVL.VN : 0.125 (unch)
Marvel Biosciences Announces Private Placement

Calgary, Alberta--(Newsfile Corp. - May 16, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased...

MBCOF : 0.0809 (-29.22%)
MRVL.VN : 0.125 (unch)
Marvel Biosciences Announces Positive Interim Results on Tau Phosphorylation with MB-204

Calgary, Alberta--(Newsfile Corp. - March 25, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.0809 (-29.22%)
MRVL.VN : 0.125 (unch)
Marvel Biosciences Announces Positive Interim Results for Autism Treatment with MB-204

Calgary, Alberta--(Newsfile Corp. - March 12, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.0809 (-29.22%)
MRVL.VN : 0.125 (unch)
Marvel Biosciences Announces Testing MB-204 on Autism by French University

Calgary, Alberta--(Newsfile Corp. - February 20, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"),...

MBCOF : 0.0809 (-29.22%)
MRVL.VN : 0.125 (unch)
Marvel Biosciences Announces Closing of Non-Brokered Private Placement

Calgary, Alberta--(Newsfile Corp. - January 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased...

MBCOF : 0.0809 (-29.22%)
MRVL.VN : 0.125 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with...

See More

Key Turning Points

3rd Resistance Point 0.145
2nd Resistance Point 0.135
1st Resistance Point 0.130
Last Price 0.125
1st Support Level 0.115
2nd Support Level 0.105
3rd Support Level 0.100

See More

52-Week High 0.190
Last Price 0.125
Fibonacci 61.8% 0.121
Fibonacci 50% 0.100
Fibonacci 38.2% 0.079
52-Week Low 0.010

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar